Takeover

ELANElanco Animal Health Inc

Pharmaceutical Preparations

Revenue
$4.7BFY2021: $4.8BFY2022: $4.4BFY2023: $4.4BFY2024: $4.4BFY2025: $4.7B
6.2% YoY
Operating margin
—
EBITDA
—
Market cap
$11.5B
Employees
1,000
$5M revenue each
Net debt / EBITDA
—
$3.3B net debt
AI in 10-K
2.1
mentions per 10K words

Takeover score 1 of 13

Fixable underperformance 1 of 7

Buyer economics 0 of 4

Catalysts 0 of 2

Financials

MetricFY2021FY2022FY2023FY2024FY2025YoYTrend
Revenue$4.8B$4.4B$4.4B$4.4B$4.7B 6.2% FY2021: $4.8BFY2022: $4.4BFY2023: $4.4BFY2024: $4.4BFY2025: $4.7B
Net income−$483M−$78M−$1.2B$338M−$232M 169% FY2021: −$483MFY2022: −$78MFY2023: −$1.2BFY2024: $338MFY2025: −$232M
Operating cash flow$483M$452M$271M$541M$560M 3.5% FY2021: $483MFY2022: $452MFY2023: $271MFY2024: $541MFY2025: $560M
Capex$159M$171M$140M$147M$276M 88% FY2021: $159MFY2022: $171MFY2023: $140MFY2024: $147MFY2025: $276M
Stock-based comp$66M$59M$46M$55M$68M 24% FY2021: $66MFY2022: $59MFY2023: $46MFY2024: $55MFY2025: $68M

Deal filings

None.

13D filers

FiledFilerFormStakeIntent
Dec 22, 2022Sachem Head Capital Management LPSC 13D/A2.0%Passive
Sep 9, 2022Sachem Head Capital Management LPSC 13D/A6.0%Passive
Dec 15, 2020Sachem Head Capital Management LPSC 13D/A5.9%Active
Nov 12, 2020Sachem Head Capital Management LPSC 13D/A5.9%Active
Oct 7, 2020Sachem Head Capital Management LPSC 13D5.9%Active

Insider trading

Open-market buys, 12 mo
$3M · 11
Open-market sells, 12 mo
$100K · 1
Net
$3M

Pay vs performance

YearCEO total compComp actually paidTSR (indexed)Peer TSR
FY2025$15M$38M74188
FY2024$15M$9M39148
FY2023$14M$17M49137
FY2022$13M−$2M40136
FY2021$12M$17M93126